3 December 2019 in Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. Regulatory Research and Medicine Evaluation
One of the prerequisites for successful application of nuclear medicine technologies is the production and clinical use of radiopharmaceuticals (RPs) of a reliably high quality. The aim of the review is to discuss specific properties of RPs, which stipulate specific approaches to their production (or preparation) and quality control. The decisive requirement for the management of RPs at all stages of their life cycle is the observance of the radiation safety rules and regulations. The paper considers the main approaches to assessing the risks of medical radiation exposure to patients and radiation protection of nuclear medicine staff. The choice of a particular quality parameter and the corresponding analytical procedure should be made taking into account the duration of the test, which, like the production time, should be comparable with the radionuclide half-life. The feasibility of the analytical procedure should also be taken into account, given the high radioactivity of the samples tested. Now that theranostics has caught on, new approaches are being developed all over the world concerning regulatory aspects of transition from preclinical studies of RPs to clinical trials, because, according to experts, this is becoming a key condition for rapid implementation of nuclear medicine achievements. The results and conclusions of the present study can be used in the development and expert review of monographs and other specifications required for RP marketing and use. The results of the analysis suggest that it is necessary to develop specific requirements and guidelines for RP testing and evaluation for their successful promotion on the EAEU market.
19 August 2022 in Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. Regulatory Research and Medicine Evaluation
The main quality attributes of radiopharmaceuticals that ensure their effectiveness and safety and are unique to their specifications are activity, radionuclide identity, radionuclide purity, and radiochemical purity. The aim of this study was to analyse the possibility of formation and methods for determination of various impurities in radiopharmaceuticals based on radionuclides of several groups: technetium-99m and rhenium-188; iodine and fluorine-18 isotopes; and gallium-68 and some other metallic radionuclides used in theranostic schemes combining radionuclide diagnostics and radionuclide therapy. The article analyses the sources for the formation of radionuclide, radiochemical, and chemical impurities; the influence of these impurities on visualisation quality and dosimetric characteristics of radiopharmaceuticals; various approaches to the methods of impurity detection and quantification; compendial requirements to the quality of radiopharmaceuticals; and research results reported in publications. The article demonstrates the need for the development and certification of Russian reference standards for testing quality attributes of radiopharmaceuticals as part of harmonisation of the State Pharmacopoeia of the Russian Federation with the Pharmacopoeia of the Eurasian Economic Union and the European Pharmacopoeia.
1 May 2022 in Russian Journal of General Chemistry
A comparative study of samarium-153 complexation with several phosphonate ligands (acyclic and cyclen-based) was carried out. Methods of quality control of the resulting complexes were proposed, and their biological behavior was determined. It is noted that the biological behavior of the radionuclide compound is the principal criterion for choosing it as an active pharmaceutical substance for the development of radiopharmaceuticals.
13 December 2024 in Drug development & registration
Introduction. The symptoms of Parkinson's disease are mainly associated with the formation of intraneuronal protein inclusions with Lewy bodies, and the progressive loss of dopaminergic neurons of the Substantia nigra and their axons. Existing diagnostic criteria for the diagnosis of Parkinson's disease often take into account symptoms occurring in the later stages of the disease. Thus, for a more accurate diagnosis in the early stages, it is necessary to confirm pathologic changes in brain tissue by molecular imaging methods such as positron emission tomography (PET) and single-photon emission computed tomography (SPECT). At the same time SPECT is a more accessible method of diagnostics of neurodegenerative diseases in comparison with PET, because of the possibility to obtain medical radionuclides for SPECT imaging using mobile generator systems, in particular 99Mo/99mTc generator. Among the formulations based on 99mTc and tropane derivatives proposed for dopamine transporter (DAT) imaging, [99mTc]Tc-TRODAT-1 (technetium-99m-labeled tropantiol) is the most effective. Currently, various compositions of the freeze-dried kits for the synthesis of [99mTc]Tc-TRODAT-1 have been proposed, facilitating the process of its production in situ, which, together with the availability of technetium-99m generator in a healthcare facility, as well as favorable pharmacokinetics, makes [99mTc]Tc-TRODAT-1 a drug of choice for routine use in clinical practice.Text. In this review, various approaches to design and optimize the composition of the freeze-dried kits for the synthesis of [99mTc]Tc-TRODAT-1, including the amount and ratio of active ingredient and excipients, synthesis conditions, in particular the temperature regime, synthesis time and pH of the reaction mixture, have been considered.Conclusion. Development and optimization of the composition of the freeze-dried kits for the synthesis of [99mTc]Tc-TRODAT-1 is an urgent task in the context of improving its use in clinical practice. Based on the published data, clear dependencies can be traced, which may form the basis for further development and optimization of the composition of the freeze-dried kits for [99mTc]Tc-TRODAT-1 synthesis for the diagnosis of Parkinson's disease and other neurodegenerative diseases by SPECT in the Russian Federation.
11 December 2020 in Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. Regulatory Research and Medicine Evaluation
Most important quality attributes of any radiopharmaceutical (RPh) are its radiochemical purity (RCP) or content of radiochemical impurities (RCIs) that have to comply with respective norms and limits. However, at present, there is no unified approach to validation of analytical methods in the context of highly radioactive samples.The aim of the study was to develop an approach to validation of methods for determination of RCI content in RPhs.Materials and methods: the authors determined the content of RCIs in a radiopharmaceutical formulation containing a complex of technetium-99m and methylenediphosphonic acid by the radiometric method after isolation of impurities from the main compound by thin-layer chromatography using silica gel and methyl ethyl ketone (for sodium pertechnetate determination) and silica gel and 13.6% sodium acetate solution (for determination of hydrolysed reduced technetium-99m). The radioactivity was registered by a chromatogram scanner with a detector of gamma-rays with energies from 0.05 to 1.5 MeV.Results: the paper analyses existing official approaches to validation of analytical procedures and compares them with the results of experimental studies described in available publications. It assesses the validation parameters for compliance with the acceptance criteria set forth in the current regulations and substantiates selectivity of chromatographic determination of impurities under the selected test conditions. Coefficients of variation for repeatability, reproducibility, and accuracy did not exceed 4.5, 2.8, and 8.9%, respectively, given the relative error of not more than 10.5%. The study demonstrated signal linearity for the 10-fold dilution of the standardised sodium pertechnetate solution, it also demonstrated correspondence between the applied and detected radioactivity when performing the test in the impurity content range of 0.5–5%. The validation procedure was associated with significant radiation burden for the personnel of the quality control laboratory.Conclusions: the authors suggested a methodological approach to validation of methods for determination of RCI content in technetium-99m-based RPhs. This approach may be used in the development of a guideline on validation of analytical methods for RCP/RCI determination in RPhs, or for introduction of relevant sections into existing documents.
28 March 2025 in Drug development & registration
Introduction. Osteoarthritis is one of the most common joint diseases. The number of patients is growing rapidly and by 2050, the number of people in the world suffering from osteoarthritis is expected to exceed 1 billion. In a number of European countries, radiosynoviorthesis is used as a treatment. It is based on irradiation of the joint synovium with intra-articular administration of various radiopharmaceuticals containing β-emitting radionuclides.Aim. Development of a radiopharmaceutical composition for radiosynoviorthesis based on rhenium-188 and hyaluronic acid as a particle stabilizer.Materials and methods. Sodium perrhenate solution, 188Re was obtained from a 188W/188Re generator "GREN-1" (JSC "SSC RF – IPPE", Russia). Eluate activity was measured on an ISOMED 2010 (PTW-Freiburg, Germany). Radiochemical purity was determined by thin-layer chromatography on thin-layer silica gel plates on aluminum substrate in acetone. The activity of chromatogram was measured on a Scan-RAM chromatogram scanner (LabLogic Systems Ltd., United Kingdom). pH was measured on S20 Seven Easy pH meter (METTLER TOLEDO, Switzerland). Particle size was determined by laser diffraction on an LA-350 device with a detection range of 0.1–1000 μm (HORIBA, Japan). Accumulation in the joint was determined on a Wizard 2480 gamma counter (PerkinElmer, USA) after intra-articular administration of the composition to mature conventional albino rats (females).Results and discussion. The study included a comparison of the physic-chemical properties of the synthesized compositions with different volume activities, the optimal concentration of hyaluronic acid, and the methods for obtaining the radiopharmaceutical composition both from the liquid and freeze-dried reagents. The biological behavior of the radiopharmaceutical composition after intra-articular administration to mature conventional albino rats (females) were studied.Conclusion. Radiopharmaceutical composition containing rhenium-188, tin dichloride and hyaluronic acid with a radiochemical purity of more than 95 % has been developed. The accumulation of the composition in the knee joint was more than 96 % 3 hours after intra-articular administration. This composition is of interest for further study as a radiopharmaceutical for radiosynoviorthesis.